## Duncan R Hewett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5272171/publications.pdf Version: 2024-02-01



DUNCAN P HEWETT

#	Article	IF	CITATIONS
1	Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i> . Haematologica, 2021, 106, 3176-3187.	3.5	11
2	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. Cancers, 2020, 12, 2149.	3.7	6
3	Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB BioAdvances, 2020, 2, 554-572.	2.4	3
4	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS ONE, 2020, 15, e0228408.	2.5	2
5	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer Letters, 2020, 475, 99-108.	7.2	22
6	Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia, 2019, 33, 457-468.	7.2	96
7	Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. Neoplasia, 2019, 21, 777-787.	5.3	53
8	A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 2019, 134, 30-43.	1.4	99
9	Using genomics to better define high-risk MGUS/SMM patients. Oncotarget, 2018, 9, 36549-36550.	1.8	2
10	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 2017, 178, 196-208.	2.5	17
11	HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. Cancer Research, 2017, 77, 5452-5463.	0.9	41
12	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. Neoplasia, 2017, 19, 972-981.	5.3	18
13	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 2017, 8, 43602-43616.	1.8	37
14	PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 106.	17.0	29
15	Therapeutic targeting of N adherin is an effective treatment for multiple myeloma. British Journal of Haematology, 2015, 171, 387-399.	2.5	25
16	Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 2015, 332, 24-38.	2.6	31
17	SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma. Neoplasia, 2014, 16, 572-585.	5.3	36